NDAORALGRANULE
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
60
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Clinical Trials (5)
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Started Feb 2018
39 enrolled
Myelodysplasia
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Started Jan 2018
44 enrolled
Iron Overload
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Started Jan 2018
45 enrolled
Hereditary Hemochromatosis
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Started Jul 2017
148 enrolled
Transfusion-dependent ThalassemiaNon-transfusion-dependent Thalassemia
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Started Mar 2017
2 enrolled
AnemiaMyelodysplastic Syndrome